Donna Supko

• Exploring key regulatory considerations for the development and marketing authorization of radiopharmaceuticals

• Touching on product type and target label claims, with a focus on the US regulatory landscape

• Uncovering future perspectives and initiatives for radiopharmaceutical regulatory affairs

• Discussing EMA’s concept paper and FDA’s project optimus

• Exploring how the field can harmonize regulations to streamline development